GB785819A - Stabilized solutions of hydrocortisone - Google Patents
Stabilized solutions of hydrocortisoneInfo
- Publication number
- GB785819A GB785819A GB28536/55A GB2853655A GB785819A GB 785819 A GB785819 A GB 785819A GB 28536/55 A GB28536/55 A GB 28536/55A GB 2853655 A GB2853655 A GB 2853655A GB 785819 A GB785819 A GB 785819A
- Authority
- GB
- United Kingdom
- Prior art keywords
- hydrocortisone
- sodium citrate
- stabilized solutions
- solution
- sodium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 title abstract 6
- 229960000890 hydrocortisone Drugs 0.000 title abstract 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 5
- 239000000243 solution Substances 0.000 abstract 3
- 235000019441 ethanol Nutrition 0.000 abstract 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 abstract 2
- 239000001509 sodium citrate Substances 0.000 abstract 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 abstract 1
- 239000003963 antioxidant agent Substances 0.000 abstract 1
- 230000003078 antioxidant effect Effects 0.000 abstract 1
- 239000008121 dextrose Substances 0.000 abstract 1
- 239000012153 distilled water Substances 0.000 abstract 1
- 238000010253 intravenous injection Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 239000004289 sodium hydrogen sulphite Substances 0.000 abstract 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Stable therapeutic compositions comprise from 5 to 20 c.c. of ethanol to approximately 100 mg. of hydrocortisone. The preparations may also contain a buffer such as sodium citrate and an antioxidant such as sodium bisulphite. When diluted with sterile dextrose solutions they are particularly useful for intravenous injection. In an example 100 mg. of hydrocortisone is dissolved in 10.52 c.c. of ethyl alcohol and the solution added to a solution of 8 mg. sodium citrate in 6 c.c. of pyrogen-free distilled water.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US785819XA | 1954-10-18 | 1954-10-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB785819A true GB785819A (en) | 1957-11-06 |
Family
ID=22144966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB28536/55A Expired GB785819A (en) | 1954-10-18 | 1955-10-06 | Stabilized solutions of hydrocortisone |
Country Status (1)
| Country | Link |
|---|---|
| GB (1) | GB785819A (en) |
-
1955
- 1955-10-06 GB GB28536/55A patent/GB785819A/en not_active Expired
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB992813A (en) | Sterilization solution | |
| GB785819A (en) | Stabilized solutions of hydrocortisone | |
| GB1100443A (en) | 17ª‡-chloroethynyl-13ª‰-ethylgonenolone | |
| GB821500A (en) | Pharmaceutical compositions comprising benactyzine and meprobamate | |
| GB830320A (en) | Injection solutions of 2-methyl-2-ú¯-propyl-1,3-propanediol dicarbamate | |
| GB816040A (en) | Improvements in or relating to therapeutically useful compositions containing reserpine | |
| GB997823A (en) | Improved pharmaceutical solutions of sodium antimonylgluconate and the production thereof | |
| GB1038912A (en) | Derivatives of ajmaline | |
| GB937598A (en) | Process for the production of reserpic acid diesters | |
| GB823242A (en) | Therapeutic compositions containing choline salts of dialkyl xanthines | |
| ES231814A1 (en) | Procedure for the preparation of a cosmetic compound for the epidermis (Machine-translation by Google Translate, not legally binding) | |
| GB804257A (en) | Liquid concentrates of sodium pentachlorophenate | |
| GB818248A (en) | Improvements in and relating to the production of adrenocorticotrophin preparation of enhanced stability | |
| ES409893A1 (en) | Cyclopentene derivatives | |
| GB1027058A (en) | Dispersions of anaesthetics for injection | |
| GB1269191A (en) | Method of combatting mastitis in mammals | |
| GB923529A (en) | Improvements in and relating to injectable preparations comprising a tetracycline antibiotic | |
| GB1134475A (en) | Guanidine derivatives | |
| GB920286A (en) | Pharmaceutical composition having anti-tubercular action | |
| ES380392A1 (en) | Procedure for the preparation of a compound of 5-nitro-furil-pirazol. (Machine-translation by Google Translate, not legally binding) | |
| GB788698A (en) | Injectable solutions of digoxin | |
| GB845586A (en) | Improvements in or relating to indoline compounds | |
| GB839376A (en) | Steroid compounds and their preparation | |
| GB959819A (en) | Improvements in or relating to podophyllinic acid ethyl hydrazide | |
| ES343303A1 (en) | Treatment of Sugar Cane |